Biogen to pay $700m to increase stake in Samsung Bioepis

This article was originally published here

Biogen has agreed to increase its stake in biopharmaceutical company Samsung Bioepis to nearly 49.9% in a deal of about $700m with its joint venture (JV) partner Samsung BioLogics.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply